64 results about "Coliform bacilli" patented technology

The invention relates to the technical field of biology, in particular to a beta-1, 4-galactosyl transferase mutant and a method for biologically synthesizing lactose-N-neotetraose by using the beta-1, 4-galactosyl transferase mutant. The invention discloses a protein, which is a protein HpgalT-186 or a protein HpgalT-146-186, a protein HpgalT-146 and a protein HpgalT-146. The protein HpgalT-186 is a protein obtained by mutating an amino acid residue at the 186th site of a wild type HpgalT; the protein HpgalT-146-186 is a protein obtained by carrying out mutation on an amino acid residue at the 186 site and an amino acid residue at the 146 site of wild type HpgalT. On the basis, a series of escherichia coli is constructed and optimized, the yield of the LNnT synthesized through shake flask fermentation of the finally obtained strain reaches 1.73-4.1 g / L, the highest yield in a 5L fermentation tank reaches 20-45.2 g / L, and efficient synthesis of the LNnT is achieved.

The invention discloses a 3 '-phosphoadenosine-5'-phosphoryl sulfate synthetase mutant and an application of the 3 '-phosphoadenosine-5'-phosphoryl sulfate synthetase mutant. Compared with a wild enzyme amino acid sequence as shown in SEQ ID NO.1, the amino acid sequence of the 3 '-adenosine-5'-phosphoryl sulfate synthetase mutant has one or two mutations in the 101 site, the 207 site and the 560 site; preferably, phenylalanine at the 101 site is mutated into tryptophan; cysteine at the 207th site is mutated into glycine; phenylalanine at the 560th site is mutated into tryptophan. The invention also provides a synthesis method and application of the 3 '-adenosine-5'-phosphoryl sulfuric acid. The APS intermediate product inhibition effect of hPAPSS1 is relieved through a point mutation technology, the substrate affinity of hPAPSS1 to ATP is improved, and a mutant enzyme with a high PAPS conversion rate is obtained; and the bifunctional enzyme hPAPSS1 is synthesized by heterologous expression of PAPS in escherichia coli, so that the acquisition of the enzyme is simplified, and the synthesis efficiency of PAPS is improved.

The present invention discloses a fermented mucus lactobacillus and its application. The present invention provides a fermented mucus lactobacillus A10 with high extracellular polysaccharide production, and its deposit number is CCTCC NO: M20242082. The fermented mucus lactobacillus A10 has strong bile salt and gastrointestinal digestion tolerance, and has obvious antibacterial effects on Escherichia coli and Staphylococcus aureus. The extracellular polysaccharide synthesized by the fermented mucus lactobacillus A10 is a Wzy type extracellular polysaccharide, which is a heteropolysaccharide composed of rhamnose, galactose, glucose, mannose, and glucuronic acid. It has good thermal stability and antioxidant activity, and can significantly scavenge free radicals. The fermented mucus lactobacillus A10 extracellular polysaccharide provided by the present invention can exert antioxidant activity by activating the Keap1-Nrf2 / ARE signaling pathway, and is expected to be developed into a natural antioxidant that interacts with Keap1-Nrf2 in a targeted manner.

The invention discloses a production method of 1, 3-dihydroxy acetone. The invention provides a method for constructing an engineering strain capable of producing 1, 3-dihydroxyacetone by using glucose, which comprises the following steps: A, inhibiting the expression of the following endogenous gene A on the basis of recipient bacteria, and enabling the recipient bacteria to express the coding gene of T7RNA polymerase T7RNAP and the coding gene of 1, 3-dihydroxyacetone phosphatase HdpA; in a 5L tank fermentation test for producing 1, 3-dihydroxyacetone by using glucose, the yield of the 1, 3-dihydroxyacetone can reach 30.1 g / L, and the conversion rate from the glucose to the 1, 3-dihydroxyacetone can reach 0.95 mol / mol. The method disclosed by the invention is of great significance to synthesis of 1, 3-dihydroxyacetone from glucose.

The invention discloses a heme oxygenase mutant and application of the heme oxygenase mutant in preparation of bilirubin through multienzyme coupling, and belongs to the field of biological catalysis engineering. The forward mutant of the heme oxygenase is obtained through a directed evolution technology, and heme can be efficiently catalyzed to synthesize biliverdin; the bilirubin is synthesized by further introducing biliverdin reductase, coupling cytochrome P450 reductase and formate dehydrogenase, and coupling the two core enzymes with foreign assistant enzymes to construct recombinant escherichia coli to catalyze heme to synthesize bilirubin. In the system, NADPH does not need to be exogenously added, the reaction time is about 4 h, the yield of bilirubin reaches 2.10 g / L, accumulation of intermediate products is not observed in the catalysis process, and the highest yield and the shortest reaction time in bilirubin synthesis reported at home and abroad at present are achieved. Compared with the traditional pig bile extraction, the method disclosed by the invention breaks through the resource limitation, is simple to operate and high in yield, and realizes efficient and green synthesis of bilirubin.

The invention discloses a casein-sourced multifunctional peptide, and belongs to the field of food science and nutriology. The casein is subjected to enzymolysis through pepsin, a method combining activity verification and mass spectrum identification is adopted, the novel multifunctional peptide YPE with a clear sequence is screened and verified, the highest ABTS clearance rate of the casein peptide YPE can reach 77.76%, the highest hydroxyl radical clearance rate of the casein peptide YPE can reach 40.18%, and the casein peptide YPE can be used for preparing the novel multifunctional peptide YPE. The inhibition rate of alpha-glucosidase reaches 30.47%, the inhibition rate of escherichia coli is 10.18%, and the limitation of an existing single-function peptide in application is overcome.

The invention relates to a colloidal gold test strip for detecting a sheep pox virus antibody as well as a preparation method and application of the colloidal gold test strip. According to the invention, firstly, a recombinant 122 protein is prepared, and the recombinant 122 protein has remarkable antigenicity and immunogenicity and can be used as a good target for diagnosing the sheep pox virus; secondly, the colloidal gold test strip for detecting the sheep pox virus antibody is prepared, a sample pad, a gold-labeled pad, a nitrocellulose membrane and a water absorption pad are sequentially arranged on a PVC base plate of the test strip, and the gold-labeled pad is coated with gold-labeled recombinant 122 protein; the test strip can simultaneously detect antibodies of the sheep pox virus, the bovine nodular skin disease virus and the goat pox virus, the sensitivity can reach 1: 128, 1: 128 and 1: 64 respectively, the test strip has no cross reaction with bovine viral diarrhea virus, foot-and-mouth disease O-type virus, foot-and-mouth disease A-type virus, orf virus, brucellosis and colibacillosis, the specificity is good, and the diagnosis coincidence rate reaches 93%.

The present invention is directed to a novel women's health probiotic formulation and methods of using the women's health probiotic formulation that inhibits both E. coli and C. albicans. Probiotics of the invention utilize Bifidobacteria and Lactobacilli to formulate a novel women's health probiotic comprising cranberry powder effective against both pathogens.

The invention discloses a genetically engineered bacterium for efficiently synthesizing 2 '-fucosyllactose as well as a construction method and application of the genetically engineered bacterium. According to the genetically engineered bacterium, a CRISPR-transposition technology is combined on the basis of a modular metabolic engineering modification strategy; a fucose module gene and a glycosyltransferase module gene in a 2 '-fucosyllactose synthesis route are subjected to genome integration, a multi-copy strain library for synthesizing 2'-fucosyllactose is constructed, and finally, a plurality of integrated expression strains for efficiently synthesizing 2 '-fucosyllactose are obtained. Compared with a plasmid type expression strain, the integrative expression strain is higher in yield and better in stability. By knockout or interruption of a glucokinase coding gene glk or a pyruvate oxidase coding gene poxB, the yield can be further increased, the unit cell yield of a glk interruption strain DH1W6G6glk:: VerA is 5.14 g / g DCW, and the yield of 2 '-fucosyllactose relative to lactose reaches 0.991 mol / mol which is the highest value of an integrated strain taking escherichia coli as a chassis at the present stage, so that the 2'-fucosyllactose has a good industrial prospect.

The present invention discloses a black yeast urate oxidase and its mutants and applications, belonging to the field of enzyme engineering. The present invention obtains the black yeast urate oxidase HorUox through deep learning, a large number of enzyme activity calculations combined with phylogenetic tree screening, and verifies for the first time that the target gene has urate oxidase activity, achieving the effect of degrading uric acid. Using a prokaryotic expression system, a pET28a (+) vector is selected to construct a recombinant plasmid and transferred into Escherichia coli BL21 (DE3). After low-temperature induced fermentation culture, the recombinant urate oxidase is expressed in a soluble manner. Through molecular docking, semi-rational design transformation, molecular dynamics simulation, etc., mutants HorUm (E183Y), HorUm (D283R), and HorUm (L287Y) are obtained, and the specific enzyme activity of the mutants is measured to be 2.02 times, 1.35 times, and 1.73 times higher than that of the wild type, respectively, and has great application potential.

The invention discloses a recombinant uricase mutant derived from arthrobacter globiforme as well as a purification method and application thereof, and belongs to the field of biological medicines. The mutant is mutated at 32-34 sites, 161 sites and 184 sites of an N end of recombinant uricase derived from arthrobacter globiforme, and the mutated amino acid sequence is as shown in SEQ ID NO: 1. On the basis of obtained uricase fermentation thalli, uricase is obtained through thalli splitting decomposition, centrifugation, nickel column affinity chromatography, liquid exchange, anion chromatography and liquid exchange, in the purification method, target protein uricase is enriched through nickel column affinity chromatography, then the purity of target protein can be increased to 95% or above through anion chromatography, and the purity of the target protein can be increased to 95% or above through anion chromatography. And finally, carrying out SUMO enzyme digestion to obtain the tag-free protein. The chromatography process is used for preparing uricase in an escherichia coli recombinant expression and purification mode, and the purity and yield of uricase are greatly improved.

The invention discloses a recombinant bacterium for producing mevalonic acid by taking glucose and acetone as co-substrates as well as a construction method and application of the recombinant bacterium, and belongs to the technical field of genetic engineering. The problems that an existing mevalonic acid biosynthesis mode is low in carbon atom economy, limited in theoretical yield and the like are solved. According to the invention, acetone carboxylase, acetoacetyl coenzyme A synthetase, 3-hydroxy-3-methylglutaryl coenzyme A reductase and hydroxymethyl glutaryl-CoA synthetase are subjected to heterologous expression in escherichia coli with an acetyl coenzyme A acetyltransferase gene atoB and a histidine protein kinase gene atoS knocked out, and self carbonic anhydrase is over-expressed; and a new way for synthesizing MVA by using glucose and acetone as a co-substrate is constructed. According to the method, one molecule of CO2 can be fixed in the biosynthesis of mevalonic acid, the yield of carbon atoms in the synthesis process of mevalonic acid is increased, the problem of low yield of carbon atoms in the synthesis process of mevalonic acid by taking glucose as a single substrate is solved, and a new thought is provided for constructing a carbon neutralization type biological manufacturing technology.

The invention relates to the technical field of modified calcium carbonate, in particular to modified calcium carbonate, which comprises the following structures: an inner core: lithium battery recycled calcium carbonate slag, which comprises 1.2-1.8 wt% of Li2CO3 and 0.5-1.2 wt% of MgCO3; the middle layer is a polydopamine (PDA) coating film, the thickness of the polydopamine (PDA) coating film is 50-80 nm, and the polydopamine (PDA) coating film is used for providing active amino (-NH2); the shell is a fluorine-containing silane and polylactic acid-glycolic acid copolymer (PLGA) composite layer, the grafting rate is larger than or equal to 90%, and the molar ratio of lactic acid to glycolic acid of PLGA is 75: 25. Quantized data of performance improvement and dispersibility are as follows: the oil absorption value is 18 ml / 100 g (compared with 28-32 ml / 100 g in the prior art), and the bulk density is 0.25 g / cm < 3 > (loose agglomeration). Functions are as follows: flame retardance: the oxygen index (LOI) reaches 34.5% (no flame retardance exists in the prior art); the antibacterial property is that the Escherichia coli inhibition rate is 99.2% (ASTM E2149 standard), and the environmental protection property is that 2.8 tons of limestone can be reduced for each ton of products, and 1.2 tons of CO2 emission can be reduced.

The present invention relates to an artificially designed high-activity O-methyltransferase gene, the nucleotide sequence of which is shown in SEQ ID NO.2. It can be used for heterologous expression of the O-methyltransferase gene, and further synthesizes scopolamine with scopoletin as a substrate. The preparation method is simple, efficient, safe and non-toxic, and can efficiently and greenly produce scopolamine on a large scale, expand the application range of scopolamine in medicine or pesticides, and improve its application value. The substrate can be simply added directly when the recombinant Escherichia coli expressing the gene is induced to express, for the production of scopolamine. It is also possible to use the purified enzyme protein, add S-adenosyl-L-methionine and scopolamine to synthesize scopolamine in vitro, and have a conversion rate of up to 92.6%.

The application discloses a metal-MOF nano-enzyme, a preparation method and application thereof, and aims to provide a metal-MOF nano-enzyme with hydrogen peroxide mimetic enzyme activity, which can significantly improve the antibacterial effect on E. coli and S. aureus and can be applied to E. coli and S. aureus bacteriostatic agents. The technical scheme is that metal salt solution is added into 2-methyl imidazole solution, and metal-MOF nano-enzyme is synthesized through ultrasonic water bath. The application belongs to the technical field of nano-mimetic enzymes and medical antibacterial technology.

The present invention discloses a selenium-rich probiotic that affects irinotecan-induced diarrhea and intestinal flora in mice, establishes an irinotecan-induced diarrhea mouse model, and administers selenium-rich probiotics by long-term oral gavage to evaluate its effects on irinotecan-induced diarrhea and intestinal flora in mice. The mice in the experimental group were given selenium-rich probiotics by oral gavage every day, and the weight, diarrhea grade, immune index, intestinal flora and ileum tissue structure of the mice were measured. The results show that selenium-rich probiotics can inhibit weight loss and reduced immune function caused by irinotecan; reduce the incidence of diarrhea and the average diarrhea grade in mice, and alleviate irinotecan-induced diarrhea in mice; reduce the content of Clostridium, Escherichia coli and Bacteroidetes associated with β-D-glucuronidase, and increase the content of bifidobacteria in the intestine; alleviate the damage of intestinal mucosa, cells and glands of mice caused by irinotecan.

The invention discloses an application of intestinal flora metabolite salicylic acid as a predictive marker of Escherichia coli calf diarrhea. The obviously up-regulated metabolite salicylic acid is screened out from the diarrhea calf feces through a non-targeted metabonomics technology, and in a group of new independent samples, it is verified through an ELISA test that the salicylic acid concentration of the diarrhea calf feces is obviously higher than that of a healthy group. ROC curve analysis shows that the area under curve (AUC) of SA for predicting escherichia coli calf diarrhea is 0.8148, and the method has good prediction capability. The invention provides a non-invasive, cheap, rapid and high-specificity prediction method, can be used for early warning and auxiliary diagnosis of Escherichia coli calf diarrhea, and has important significance for guiding clinical precise medication and reducing the death rate of calves.

The invention belongs to the technical field of biology, and provides application of bombyx mori cytokine-like protein as an active ingredient of a medicine for inhibiting bombyx mori nuclear polyhedrosis viruses, the amino acid sequence of the bombyx mori cytokine-like protein is shown as SEQ ID NO: 1, and the protein can inhibit replication of the bombyx mori nuclear polyhedrosis viruses. In addition, the invention also provides a bombyx mori cytokine-like protein, a bombyx mori cytokine-like plasmid is amplified through a PCR primer group to obtain a bombyx mori cytokine-like amplification product, then the bombyx mori cytokine-like amplification product and the bombyx mori cytokine-like plasmid are subjected to double enzyme digestion through incision enzyme, enzyme digestion products are purified and then connected through T4 ligase, and the bombyx mori cytokine-like protein is obtained. And transforming Escherichia coli DH5 alpha competent cells, screening positive clones, and extracting plasmids.

Disclosed is an antibacterial material, including polyhexanide, guanidinized polymer and hydroxycarboxylic acid. In addition, disclosed are an antibacterial material solution, an antibacterial treatment method for a PVC oxygen inhalation tube of a respiratory humidifier, and a PVC oxygen inhalation tube of a respiratory humidifier. The present invention uses an antibacterial material of a specific composition, and obtains a PVC oxygen inhalation tube of a respiratory humidifier after antibacterial treatment. Compared with the prior art, the PVC oxygen inhalation tube of a respiratory humidifier has better antibacterial performance against Staphylococcus aureus and Escherichia coli.

The application discloses a novel group B meningococcal outer membrane protein bifunctional carrier, relates to the technical field of biopharmaceutical processes, and discloses a group B meningococcal outer membrane protein bifunctional carrier and application of the bifunctional carrier in a meningitis combined vaccine. The bifunctional carrier is human H factor binding protein fHbp, and comprises two kinds of recombinant proteins BA and BB, and the amino acid sequences of the two kinds of recombinin proteins are SEQ ID No. 62 and SEQ ID No. 63 respectively. The BA protein is coupled with group A capsule polysaccharide to form a group A combined vaccine, the BB protein is coupled with group C capsule polysaccharide to form a group C combined vaccine, and the two are mixed to form a group ABC triple vaccine. Each dose of the triple vaccine contains 40 μg of group A / C polysaccharide, 160 μg of BA / BB protein in total and 1.0 mg of aluminum adjuvant. The BA and BB proteins are expressed by E. coli, are broken by high-pressure homogenization, and are purified by anion exchange chromatography, and the purity is greater than or equal to 95%. The triple vaccine can simultaneously induce immune responses to groups A, B and C of meningitis, the serum bactericidal titer is greater than or equal to 1:32 after primary immunization, and the titer is maintained for more than 56 days after three immunizations.

This invention discloses a recombinant *E. coli* strain for producing phenyllactic acid, a lactate dehydrogenase mutant, a whole-cell catalytic method for preparing phenyllactic acid, and the application of the aforementioned recombinant *E. coli* strain or lactate dehydrogenase mutant in the catalytic preparation of phenylpyruvic acid from phenyllactic acid. This invention significantly improves catalytic efficiency by modifying the 52nd amino acid of lactate dehydrogenase through site-directed mutagenesis. After mutating glutamine (Q) to valine (V) at position 52 of the *Lactobacillus mucosa* lactate dehydrogenase, the catalytic efficiency is significantly improved even at low cell density (OD). 600 =15) and substrate 15 g / L conditions, almost complete conversion was achieved; and combined with high-density catalysis and surface display optimization, the yield of phenyl lactic acid was increased while the downstream separation and purification costs were significantly reduced, greatly enhancing the potential for industrial production.

The present invention relates to lactic acid bacterial strains capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.

The invention belongs to the field of bioengineering, and particularly relates to a method for efficiently synthesizing recombinant human lactoferrin. The invention provides a synthetic method of recombinant human lactoferrin, which comprises the following steps: constructing escherichia coli recombinant host cells, performing fermentation culture, and separating and purifying the recombinant human lactoferrin, optimizing fermentation culture conditions, so that the fermentation process is in an optimal state, the yield of the recombinant human lactoferrin can be obviously improved, and the yield of the recombinant human lactoferrin can be obviously increased. And the large-scale production requirement is met. The efficient purification process established under the synthetic method can gradually remove impurities, so that the product purity is improved, the endotoxin content is lower than 10EU / mg protein, the safety standard of infant food is met, and a guarantee is provided for producing high-quality infant milk powder.

The application discloses a semi-chemical synthesis method of an N-terminal domain of matrix metalloproteinase inhibitor-2 (N-TIMP2) and application thereof. The N-TIMP2 is divided into three fragments, wherein a key tyrosine post-translational modification site is located in the fragment 2; the polypeptide resins of the fragment 1 and the fragment 2 are synthesized by using a solid-phase polypeptide synthesis technology, and the fragment 1 and the fragment 2 with a C-terminal hydrazide are obtained after cleavage, deprotection, extraction and purification; the fragment 3 is obtained by combining an E. coli recombinant expression technology and a three-step one-pot selective protection reaction of side chains of mercapto; the fragment 1, 2 connecting product is obtained through a first-step natural chemical connecting reaction; the full-length linear protein is obtained through a second-step natural chemical connecting reaction, desulfurization and deprotection; and finally, the N-TIMP2 protein is obtained through a refolding reaction. The semi-chemically synthesized N-TIMP2 protein has a comparable MMP-14 inhibiting activity to the N-TIMP2 protein obtained by using the E. coli recombinant expression technology.

The present invention discloses an antimicrobial peptide or its salt, a pharmaceutical composition and application, belonging to the field of biotechnology. The amino acid sequence of the antimicrobial peptide is shown in SEQ ID NO: 1, and it has a broad-spectrum antibacterial effect, and has a strong antibacterial effect on various Gram-positive bacteria such as Staphylococcus aureus, Enterococcus and Streptococcus, and various Gram-negative bacteria such as Escherichia coli, Acinetobacter baumannii and Pseudomonas aeruginosa, with strong antibacterial activity, a broad antibacterial spectrum and low toxicity. The present invention also provides derivatives and salts of the antimicrobial peptide, and the antimicrobial peptide, the derivatives and salts of the antimicrobial peptide are used in the research and development of various antimicrobial products or / antimicrobial drugs, and are used in the treatment of bacterial infectious diseases, with significant advantages and broad application prospects.

The application discloses a beta-lactoglobulin mutant, a preparation method and application, relates to the technical field of genetic engineering, and the amino acid sequence of the beta-lactoglobulin mutant is shown as SEQ ID NO. 1; the preparation method is as follows: designing a forward primer, a reverse primer, a forward mutant primer and a reverse mutant primer; using a wild-type beta-Lg plasmid as a template, a mutant DNA segment is obtained by using overlap extension PCR technology; after the mutant DNA segment is connected with an empty vector, the obtained recombinant plasmid is transformed into an E. coli competent cell, cultured and identified; the recombinant plasmid is transformed into the E. coli competent cell, cultured and lysed; the cell supernatant is collected, purified, and the beta-lactoglobulin mutant is obtained; the application improves the binding property of the beta-lactoglobulin with specific IgE antibodies, enhances the immunological activity of the beta-lactoglobulin allergen, and enhances the sensitivity and specificity of the allergen specific IgE antibody detection result.

The invention discloses Lactobacillus johnsonii and application thereof in alleviating intestinal damage caused by plateau hypoxia. The composite bacterial agent of the composition of Lactobacillus johnsonii YH1136 and Bacillus subtilis BS01 provided by the invention can effectively prevent, treat and alleviate intestinal damage caused by plateau hypoxia exposure. The composite bacterial agent can increase the expression levels of tight junction proteins such as Claudin‑1, Occludin and ZO‑1, and restore the intestinal barrier function damage caused by plateau hypoxia exposure; restore the expression level of intestinal pro-inflammatory cytokines; reduce the level of harmful bacteria Escherichia coli, and increase the level of beneficial bacteria Lactobacillus; improve diarrhea; and maintain body weight. The composite bacterial agent provided by the invention can be used to prepare a medicine for alleviating intestinal damage caused by plateau hypoxia exposure and a composition thereof, can also be used as an auxiliary product of existing therapeutic drugs and treatment methods, and can also be used as a microecological preparation in medicines or health products, and has a very broad application prospect.

The invention provides a mutant of a Yigf gene encoding protein and application of the mutant in preparation of NMN, belongs to the technical field of molecular biology, and particularly provides the mutant of the Yigf gene encoding protein, the 80th leucine of the amino acid sequence SEQ ID NO.3 is mutated into isoleucine, and the 80th leucine of the amino acid sequence SEQ ID NO.3 is mutated into isoleucine. The coding gene of the mutant is as shown in SEQ ID NO. 2; a recombinant bacterium containing the coding gene of the mutant; according to the invention, it is found for the first time that 80th leucine in an amino acid sequence of Yigf gene coding protein of escherichia coli is mutated into isoleucine; the synthesis level of NMN can be effectively improved, and generation of by-products is reduced.

The invention discloses a coding gene of cutinase CutBJB6 for synthesizing a plurality of fatty acid ethyl esters from a Lacnella arida source and an application of the coding gene of cutinase CutBJB6. The amino acid sequence of the cutinase CutBJB6 is as shown in SEQ ID NO. 1, and the nucleotide sequence of the coding gene of the cutinase CutBJB6 is as shown in SEQ ID NO. 2. The invention belongs to the technical field of biosynthesis, and particularly discloses a coding gene of the Lacnellada-derived cutinase CutBJB6 and construction of an escherichia coli expression vector carrying the gene, and also discloses application of the Lacnellada-derived cutinase CutBJB6 in catalytic synthesis of ethyl butyrate, ethyl valerate, ethyl hexanoate, ethyl caprylate and ethyl caprate in a water-phase system. The invention further discloses a preparation method of the Lacnellada-derived cutinase CutBJB6 and application of the Lacnellada-derived cutinase CutBJB6 in the field of biosynthesis of the Lacnellada-derived cutinase CutBJB6. The invention firstly provides the cutinase CutBJB6 which has the capability of synthesizing fatty acid ethyl ester in a water phase system and is derived from the Lacnella arida and the coding gene of the cutinase CutBJB6.

The invention provides compositions and methods for reducing symptoms of inflammation by administering therapeutically effective amounts of (a) (1) enterotoxic E. coli heat labile detoxified toxin A subunit that interferes with the function of ADP-ribosylation factor and inhibits ADP-ribosylation, or (2) A1 subunit that interferes with the function of ADP-ribosylation factor and inhibits ADP-ribosylation, or both (1) and (2), and (b) a carrier that causes internalization of the A subunit or A1 subunit, or both, into cells.